Evidence map›Paper›PMID 36134725›Full record

ArticleACS biomaterials science & engineering2022

IL-10-Functionalized Hydrogels Support Immunosuppressive Dendritic Cell Phenotype and Function.

Nicholas M Beskid, Elizabeth M Kolawole, María M Coronel, Brandon Nguyen, Brian Evavold, Andrés J García, Julia E Babensee

Open access · greenAbstract read
In one paragraph

Article in ACS biomaterials science & engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Biomaterial-Based Therapeutic Delivery of Immune Cells.Advanced healthcare materials · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nicholas M BeskidGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive NW, Atlanta, Georgia 30318, United States.ORCID 0000-0002-7026-6424
Elizabeth M KolawoleDepartment of Pathology, University of Utah School of Medicine, 15 North Medical Drive East, Suite 1100, Salt Lake City, Utah 84112, United States.
María M CoronelGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive NW, Atlanta, Georgia 30318, United States.ORCID 0000-0001-9661-7221
Brandon NguyenParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive NW, Atlanta, Georgia 30332, United States.ORCID 0000-0001-8175-299X
Brian EvavoldDepartment of Pathology, University of Utah School of Medicine, 15 North Medical Drive East, Suite 1100, Salt Lake City, Utah 84112, United States.
Andrés J GarcíaGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive NW, Atlanta, Georgia 30318, United States.ORCID 0000-0001-6602-2518
Julia E BabenseeParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive NW, Atlanta, Georgia 30332, United States.ORCID 0000-0002-7065-9172
Georgia Institute of Technology · USUniversity of Utah · US

Funding

Hydrogels for hMSC delivery & engraftmentR01AR062368 · NIAMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2012 to 2022
$3.5M
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet graftsU01AI132817 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI GARCIA, ANDRES J, SHIRWAN, HAVAL · 2017 to 2021
$2.0M
T32 Research Training Program in ImmunoEngineeringT32EB021962 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI JULIA E BABENSEE · 2017 to 2026
$1.9M
Innovation & Leadership in Engineering Technologies and Therapies for DiabetesT90DK097787 · NIDDK · GEORGIA INSTITUTE OF TECHNOLOGY · PI BABENSEE, JULIA E · 2012 to 2017
$621k
Multifunctional Biomaterial for Amelioration of MS in Murine EAE ModelR21EB019166 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI BABENSEE, JULIA E · 2015 to 2016
$432k
Innovation and Leadership in Engineering Technologies and Therapies for DiabetesR90DK098981 · NIDDK · GEORGIA INSTITUTE OF TECHNOLOGY · PI BABENSEE, JULIA E · 2012 to 2016
$339k
NIAID NIH HHS U01 AI132817NIAMS NIH HHS R01 AR062368NIBIB NIH HHS R21 EB019166NIBIB NIH HHS T32 EB021962NIDDK NIH HHS R90 DK098981NIDDK NIH HHS T90 DK097787
6 · The paper itself

Abstract

Biomaterial systems such as hydrogels enable localized delivery and postinjection modulation of cellular therapies in a wide array of contexts. Biomaterials as adjuvants have been an active area of investigation, but the study of functionalized biomaterials supporting immunosuppressive cell therapies for tolerogenic applications is still nascent. Here, we developed a 4-arm poly(ethylene-glycol)-maleimide (PEG-4MAL) hydrogel functionalized with interleukin-10 (IL-10) to improve the local delivery and efficacy of a cell therapy against autoimmune disease. The biophysical and biochemical properties of PEG-4MAL hydrogels were optimized to support dendritic cell (DC) viability and an immature phenotype. IL-10-functionalized PEG-4MAL (PEG-IL10) hydrogels exhibited controlled IL-10 release, extended the duration of DC support, and protected DCs from inflammatory assault. After incorporation in PEG-IL10 hydrogels, these DCs induced CD25+FoxP3+ regulatory T cells (Tregs) during

Indexed as

HydrogelsInterleukin-10Biocompatible MaterialsDendritic CellsEthylenesForkhead Transcription FactorsMaleimidesPhenotypePolyethylene GlycolsBiocompatible MaterialsEthylenesForkhead Transcription FactorsHydrogelsInterleukin-10MaleimidesPolyethylene Glycolsdendritic cellshydrogelimmunosuppressionmultiple sclerosistolerance

Identifiers

PMID36134725
PMCPMC10231409
OpenAlexW4296613535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.